All News

Found 613 articles

• Meet This Largely Over-Looked Phase 3 Alzheimer's Company

  2/1/2017

• Why Celgene Should Consider Buying Rival Biogen

  1/24/2017

• Earnings Preview: Here's a Look at What to Expect From 7 Biopharmas

  1/23/2017

• JPM17: Biotech IPO Guru Vivek Ramaswamy Expects More Startups, Deals in 2017

  1/12/2017

• JPM17: New Biogen CEO on Groundbreaking Alzheimer's Trial and the Company's Future

  1/12/2017

• 13 Reasons to Watch the J.P. Morgan Healthcare Conference Next Week

  1/6/2017

• This is Why Biogen’s Stock is Set to Soar in 2017

  12/22/2016

• Acadia Stock Screams Upward; Primary Endpoint Met in Phase II Study of Pimavanserin for Alzheimer’s

  12/21/2016

• Meet Biogen's New CEO

  12/21/2016

• Celgene, Evotec AG Ink $295 Million Drug Discovery Pact

  12/16/2016

• Biogen Ends the Year by Slashing Another 200+ Jobs as It Exits Manufacturing in Massachusetts

  12/16/2016

• Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study

  12/15/2016

• Top 3 Most Profitable Companies in Biotech

  12/14/2016

• As Biogen's Drug Shines, Eli Lilly Releases Detailed Results of Its Own Failure Solanezumab

  12/9/2016

• Alzheon Presents Analyses From Phase III Clinical Studies Showing Largest Clinical Effects Of Tramiprosate, The Active Molecule Of ALZ-801, In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease

  12/9/2016

• All Eyes Will Be on Biogen and Its Much-Anticipated Alzheimer's Data Tomorrow

  12/9/2016

• Why Biogen Could Rebound in 2017

  12/7/2016

• Eli Lilly to Begin Axing Hundreds of Sales Jobs Early 2017

  12/6/2016

• Fear of Layoffs Loom Over Eli Lilly Employees After Alzheimer's Setback

  12/1/2016

• 10 Biotechs That Could be Bought Out Thanks to the Trump Bump

  11/30/2016